Novartis CEO calls for simpler biosim rules, end to rebate wall by Eric Sagonowsky Friday, April 13, 2018 Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.
FiercePharmaAsia—Novartis, Samsung Bioepis, Takeda and more by Angus Liu Friday, April 13, 2018 Novartis faces doctor kickback allegations in China, Samsung and AbbVie ink a Humira biosim settlement, and Takeda seeks financing for a Shire bid.
No March madness for pharma ad spending as Humira tops list by Beth Snyder Bulik Wednesday, April 11, 2018 AbbVie’s Humira and Pfizer’s Lyrica remained in the top two spots for pharma TV ad spending in March, according to realtime TV ad tracker iSpot.tv.
Booker: Pharma should've cut prices with tax savings—but didn't by Eric Sagonowsky Wednesday, April 11, 2018 Top drugmakers benefited from tax reform, but a new report says several companies passed that benefit on to shareholders and executives, not to patients.
What would a Shire buy look like for Pfizer, Amgen or AbbVie? by Carly Helfand Friday, April 6, 2018 With Takeda weighing a Shire bid, other companies may be shopping the struggling biotech, too. Analysts are figuring out the who, what and how.
AbbVie's Humira wins another biosim reprieve with Biogen deal by Eric Sagonowsky Thursday, April 5, 2018 AbbVie shielded Humira from another U.S. biosims threat in a deal that makes it "increasingly unlikely" any copycats will launch here before 2023.
Celgene, AbbVie extract pricing gains as Gilead, J&J meds net less by Eric Sagonowsky Tuesday, April 3, 2018 Higher net prices for Humira and Revlimid fueled growth in the fourth quarter for AbbVie and Celgene, respectively, a report found.
New Allergan character bows for Zenpep by Beth Snyder Bulik Monday, April 2, 2018 Eddie the Enzyme is ready to break down food and take on the competition in pancreatic enzyme products.
Will tax-boosted Big Pharma beat Takeda to a Shire deal? by Carly Helfand Friday, March 30, 2018 Takeda hasn’t even approached Shire’s board with a buyout offer yet, but competing bidders could jump in quickly, thanks to U.K. takeover rules.
AndroGel trial do-over slashes AbbVie damages to $3M by Eric Sagonowsky Tuesday, March 27, 2018 AbbVie scored a major reduction of damages in a retrial of an AndroGel liability case brought by plaintiff Jesse Mitchell.
